news

June 28, 2011 Alachua, FL. Altor BioScience and Florida Biologix team up to move an important interleukin-15 (IL-15)-based immunotherapeutic, ALT-803, to the clinic as a novel cancer therapy. ALT-803, a proprietary IL-15 super agonist/IL-15Rα-Fc fusion complex, has demonstrated impressive anti-tumor activities in various pre-clinical cancer models and could potentially make a life-changing difference for patients with solid and hematological tumors.

Edinburgh, United Kingdom 10th September, 2010. Synpromics announces its incorporation as Scotland’s latest biotech company. The new company aims to focus its activities in the area of synthetic mammalian biology and has acquired a number of patent applications that arose out of inventions by its founder and managing director; Dr Michael Leslie Roberts.

Living Cell Technologies Receives Grant from the Juvenile Diabetes Research Foundation International for DIABECELL® NZ Clinical Trial

29 April 2010 – Sydney, Australia, Auckland, New Zealand– Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) announced today the quarterly cash flow report for the quarter ended 31 March 2010. The Appendix 4C is attached. The cash balance at the end of the quarter was $4,090,696 compared to $5,494,841 at 31 December 2009. This decrease reflects the development of the lead product DIABECELL®.

Net operating cash outflows were $1,257,133 compared to $1,676,991 last quarter.

The Gene Therapy Review announces its new partnership with EBSCOhost, an agreement that will see its content distributed worldwide in a multitude of libraries. Articles submitted to the Gene Therapy Review will now also be directly available in school, college, university, hospital, governmental, corporate and public libraries.

The year 2009 was quite turbulent for gene therapy companies, with lay-offs, bankruptcies and general financial crisis. Earlier 2008 FDA refused US based Introgen’s Biologics License application (1) and during 2009 now bankrupt Introgen sold it’s GMP facilities and other remaining assets to Vivante GMP Solutions, ceasing to exist as gene therapy company. Similarly other gene therapy companies have had difficulties on getting their products to the market, especially with the economic crisis hindering their financing.

Diamond BioPharm Limited, announce a cutting edge first. As well as the submission of a Marketing Application for a Gene Therapy Product in December 2009 - on behalf of Amsterdam Molecular Therapeutics, a leading company in the development of gene-based therapies - the dossier is also in eCTD format. Maureen Graham, founder of Diamond BioPharm Limited said that it was a major achievement for both companies and is both proud and honoured that Diamond BioPharm Limited has had an opportunity to be part of this innovative project.

Important facts:

Today Ark released the negative opinion of EMEA for it's crucial Cerepro- drug.

A strategy that combines gene therapy with blood stem cell therapy may be a useful tool for treating a fatal brain disease, French researchers have found. These findings appear in the 6 November 2009 issue of the journal Science, which is published by AAAS, the nonprofit science society.

Targeted Genetics Corporation (NASDAQ: TGEN) today announced the sale to Genzyme Corporation of certain assets, including manufacturing technologies and other adeno-associated viral (AAV) vector technology, for up to $7 million in cash. The purchased assets consist primarily of patents, know-how and manufacturing-related equipment. Genzyme also received a license to use certain technology and materials necessary for manufacturing AAV vectors.